iTeos to Present at the 39th Annual J.P. Morgan Healthcare Conference

NEXT STORY
InflaRx Completes Enrollment in Vilobelimab (IFX-1) European Phase II Study in ANCA-associated Vasculitis
PREV STORY
SpringWorks Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Priority Review Granted to BeiGene’s Supplemental New Drug Application in China for Tislelizumab in Urothelial Carcinoma

author_avatar
NASDAQ Market News

MDxHealth Opens New Service and Research Laboratory in The Netherlands

COMPANY ANNOUNCEMENT                                                                  HERSTAL, BELGIUM - 07:00 CEST, October 5, 2017 - MDxHealth ...

author_avatar
NASDAQ Market News

Five Prime Therapeutics Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity with FPT155

Poster featured at 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsCompany anticipates filing ...

author_avatar
NASDAQ Market News